SME Innovation fund


2019-09-30T17:00:00 2 3
Are you a start-up or a small medium sized enterprise working in the space of delivering improved healthcare? Do you have the potential to change how healthcare is delivered? The SME Innovation Fund can provide the support you need to help your business grow.

Ideas (Clinical trials and evidence)

Innovation 'Elevator Pitch':
A platform combining the best of WhatsApp, LinkedIn and Slack with an innovative, compliant architecture to provide a universal data and messaging layer for health care.
Overview of Innovation:
Need

Out-dated and overly bureaucratic health communications are a source of enormous inefficiency and frustration for doctors, nurses and patients. 600,000 clinicians in the UK alone have turned to consumer messaging solutions like WhatsApp to solve the problem. But these solutions have been ruled inappropriate for use in health use under GDPR and sparked 1000 NHS disciplinary actions to date.

Innovation

1. Unique “serverless” network architecture scales users exponentially with linearly scaling costs.
2. Free and ethical: Core functions are free for everyone, with no need to monetise sensitive data to pay for servers
3. Compliant by design: GDPR & health privacy standards built in to the architecture itself. All data stored in phone.
4. Super-simple user interface is easy to adopt and easy to use, enabling a bottom-up approach to market.

Market

Hospify is a market-dominance play, designed to capture the majority of healthcare professionals in the UK (2.9m), EU (23m) & South America. Most users will join at least two Hubs (employer Hub, union Hub, specialism Hub, pharmaco Hub, insurance Hub).

Approach
  • Simplicity and trust of core messaging drives bottom-up adoption by nurses and care workers, led through employer and union hubs.
  • Broadcast messaging function enables replacement of both hospital pagers and costly SMS systems, driving adoption employers & CCGs.
  • Platform is built out using APIs to provide a messaging layer for other, more specialised workflow and data-driven services, allowing them to function within an ecosystem.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Wellness and prevention of illness / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
A net budget impact of Hospify for the whole of the NHS community staff population, with a projected 51.2% uptake, has been calculated to be £166m p.a. by 2023/4. Please see the attached Budget Impact Model, constructed in collaboration with Kent Surrey Sussex AHSN, for methodology and more detailed analysis.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
An analysis of the impact on the WM population specifically has not yet been carried out, but the attached Budget Impact Model includes an analysis of the similarly sized Kent Surrey Sussex region, with 12,565 community healthcare staff. The impact on this regions was calculated as £10.48m p.a. by 2023/4. Again, please see the attached Budget Impact Model for more detail.
Current and planned activity: 
The free version of Hospify, available via the Apple and Android app stores, was released in February 2018 and now has around 5000 clinical users in more than 100 hospitals and clinics throughout the UK. 

The paid version of the platform, the Hospify Hub (https://hub.hospify.com) has been available as a live beta from April 2019 and is currently being trialled by around 20 heathcare organisations, including:
  • Birmingham Community NHS Trust
  • University Hospitals North Midland
  • Cambridge & Peterborough NHS Trust
  • Lincolnshire Community NHS Trust
  • Corby NHS Health Centre (Lakeside+)
  • The GP Service telehealth company 
  • Royal Blackburn
In addition, following two paid trials, we have an agreement in place with UNISON Health, the largest public sector health union in the country with around around 500,000 members, to begin selling Hospify to its 200+ branches once the release version of the platform goes live in September 2019.

We are also on the Kent Surrey Sussex AHSN digital health accelerator programme.
What is the intellectual property status of your innovation?:
Hospify Limited owns all IP in the Hospify platform. We have UK trademarks for name and logo in place, and EU, US and Colombian trademarks in process.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Regional Scalability:
The primary region for the initial rollout of the Hospify Hub from September 2019 will be the West and North Midlands. Hospify works very closely with UNISON Regional Branch team based out of the UNISON office in Birmingham, which co-ordinates the union branches throughout this region.
 
From September Hospify will, with the active support of UNISON’s regional team, be selling the Hospify Hub to UNISON branches in the region and promoting the platform’s adoption among nurses and support staff who are also union members.
 
This will allow us to generate revenues while also building an active userbase in multiple hospitals in the region. Once we have identifiable user clusters, we will begin approaching the relevant hospital authorities, and encouraging them to approve Hospify for use at work by their clinical teams.
 
This approach has already proven to work at the Royal Stoke and Wye Valley, where the UNISON activity has led directly to constructive discussions with the hospital management.
Measures:
Healthcare staff currently use either bleeps or phones when it comes to communication, neither of which are efficient nor particularly effective in a complex, modern healthcare environment, or indirect instant messaging solutions such as SMS or WhatsApp, which are not legally compliant with patient safety and data protection rules.

Hospify is a platform designed to allow healthcare professionals and patients to collaborate and connect using instant and trusted communication across dispersed teams and extended clinical networks and in the process:
  • Produce both time and cost savings for staff
  • Cut through a layer of administration, improving efficiency
  • Reduce reliance on SMS
  • Provide security controls without fear of transgressing EU GDPR requirements
  • Offer an easy interface for staff and patient surveys
  • Capture and store data to help improve patient outcomes by cutting unnecessary appointments and reducing adverse events.
A Budget Impact Analysis was commissioned from Kent Surrey Sussex AHSN by Hospify in order to assess, from the perspective of the healthcare system, the impact of such a communication platform both broadly in terms of costs and benefits and in a second instance, specifies to select pilot sites in a community healthcare setting. As there is no quantified evidence of Hospify working in practice within a community environment, results from external research on instant messaging systems was collected and used to show the potential outcomes.

The NICE budget impact template was used as a starting point to create a model for instant messaging systems and modified accordingly to fit the Hospify analysis. The full study and health economic framework for future studies can be found in the attached Budget Impact Analysis document. Post-funding, Hospify intends to conduct its own quantified study using this framework. The planned pilot site is currently Frimley Park NHS Trust in Surrey, but it would be possible to relocate this to the West Midlands.
Adoption target:
Hospify aims to have 30% of the 131,072 NHS staff in the West Midlands to be using the free version of the app by the end of 2023, with a higher proportion of adoption (51%) among the region’s 18,879 community healthcare staff.
 
Around 10% of these would be anticipated to be using the Hospify desktop app, paid for via the Hospify Hub.
 
Read more
Hide details
James Flint 05/07/2019 - 18:27 Screening Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
An entirely novel management system for ostomy care which will improve the psychological wellbeing and quality of life for ostomates through empowering aesthetics and functional advantages utilizing innovative material technology.
Overview of Innovation:
A stoma is a surgical opening made in the abdomen often as a result of bowel disease or cancer. This bypasses the normal bowel function and diverts output into a colostomy bag, which the patient must wear all day, every day.
There are almost 200,000 ostomates in the UK and the global ostomy market is estimated to reach $3.4 billion by 2020 due to the increasing prevalence of bowel disease and cancer. With an ageing population and the decreasing age of stoma patients, it is a rapidly expanding market. Current designs cater to the practical collection of output and largely ignore the dramatic psychological effects of living with this condition. “The stoma itself wouldn’t worry me in the slightest. It’s the fact I shit in a bag and carry it around with me all day.”
 
Recent studies into body image concerns of people with disabilities, found that  “feelings of physical inadequacy and unattractiveness” were common themes. Functional issues with available products persist, including leakages, inadequate adhesive and unpleasant odours. Skin problems are extremely common for ostomates and The Association of Coloproctology estimates that 2/3 of paitents suffer from skin problems during their lives. Available products do little to alleviate the drastic changes in body image and self-confidence. Nor do they challenge the social stigma.
 
Our innovation will reduce the psychological impact and loss of dignity ostomates face. It comprises a unique method of skin attachment showing a marked reduction in skin inflammation than current designs. We utilize existing technologies which have previously never been used in this application in order to deliver enhanced functionality; It is leak-proof, odour resistant, and is more aesthetically pleasing than available alternatives. The intricately embossed stoma covering and collection system has been inspired by tattoos and lingerie and is specifically designed for temporary wear; swimming, the beach, intimate occasions. Times when exposing a typical appliance could cause embarrassment. Our user research showed over 25% of people never swam or showed their stomach in public due to lack of confidence or embarrassment. In fact we had a positive response of over 88% from participants, and many spontaneous calls to purchase showing a significant market need. 
Stage of Development:
Trial stage - Trial stage to prove that the idea actually works as intended
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Innovation and adoption / Person centred care
Benefit to NHS:
Stoma surgery as a result of inflammatory bowel disease and cancer poses significant economic burdens to the NHS. A recent report claimed that £918k is spent on ostomy products each year. Stoma patients “provide a significant cost pressure to the NHS. Ensuring that patients are prescribed appropriate appliances and accessories can greatly improve their quality of life.” (Medicines Optimisation Work Programme 2017) Additionally, the cost to the NHS of caring for patients with wounds is estimated to be around 3% of the total NHS budget. In assuring the correct psychological care of patients and by providing products that will reduce skin inflammation, this will certainly improve the patients overall management thus reducing hospital admissions and therefore pressure and cost to the NHS.

Research by Barista, found that the relationship between an ostomate and their pouch is “permeated by negative feelings, significant changes in [the] physical, psycological and sexual [and] social relationships.” Our own research has found that many ostomates are unable to return to work or able to persue social or intimate relationships. This downward spiral can lead to serious depression, debilitating anxiety and social isolation which has additional social and economic consequences.

A functioning medical appliance, though crucial, is not the only patient requirement. By addressing their psychological needs, it will contribute to their increased quality of life and significantly improve the overall management of their condition. By empowering them to overcome the psycological impact of living with an ostomy, it will allow them to participate to their full potential in society and the wider economy. Allowing them to persue social and intimate relationships, recover from surgery quicker, ultimately return to work earlier and begin contributing to society faster. Not to mention being able to maintain a healthy lifestyle through exercise and other physical activity. Our innovative products will not only benefit the well being and mental health of individual patients, but in fact contribute to a much wider range of positive social and economic outcomes.
 
This has potential for expansion outside the ostomy market as the technology is suitable for a number of medical applications. Variations in the design could be developed for people with feeding tubes, wounds from conditions such as diabetes, bad scarring from surgery or burns and also as transdermal patches delivering drugs.
Initial Review Rating
4.20 (2 ratings)
Benefit to WM population:
We are curently working with the BizzInn Accelerator programme and have partnered with Birmingham University Hospital, the MD-TEC, the Birmingham Trauma Healthcare Technology Cooperative and Leeds Colorectal HTC in order to continue the development of our product.
 
Birmingham is the second largest city aside from London in the UK and has a number of National Health Services and Hospitals situated in and around the city. It is a hub of innovation and healthcare and is a perfect location for our company to develop and thrive. Birmingham University Hopsital in particular has the largest critical care unit in Europe.
 
During 1st January 2015 and 31st December 2016, there were over 275 patients with a stoma admitted to Birmingham University Hosiptal. The majority of these patients were aged between 37 and 66 although there were also high numbers of pateints aged between 27 and 36 and above 67. In our user research we have identified these user groups to suffer from real psycological issues as a result of stoma surgery and therefore we believe are the exact people our product will benefit. Our product will ensure better management and overall well being which in turn will allow them to return to work faster thus allowing them to contribute to West Midlands society and economy earlier.
 
The need and benefit to patients located in the West Midlands (and across the UK) has been previously highlighted and we feel that developing such a novel and innovative project here will only serve to benefit the population and the involved partners in both financial return and recognised acclaim. We are also applying for various other funding initiatives including Innovate UK which if accepted, will bring funds and partnerships to the region which will in due course bring further economic benefit. 
Current and planned activity: 
We have an aesthetic prototype and a working prototype will be initiated with funding. With our team we have developed strategic objectives to continue development.
 
WP0:MVP development and testing, User & Market research - complete
WP1:Project Management
WP2:Public and Patient Involvement (University of Birmingham (UoB) and Bowel & Cancer Research UK)
WP3:Adhesive development and lab testing (UoB, MD-TEC, HTC)
WP4:Product Prototype Manufacture (sub contracted)
WP5:Usability Tests (UoB & MD-TEC)
WP6:Clinical Trials (small scale as Class 1 non-sterile device)(UoB and MD-TEC)
WP7:CE regulations (MD-TEC)
 
On completion of objectives, we will be ready for commercialization. At this time we will investigate NHS commissioning and procurement, along with those for private healthcare providers. We will evaluate the possibility of online sales and explore partnerships with device distributors. We have already received interest to date and will re engage once further development has been completed. 
What is the intellectual property status of your innovation?:
UK patent applied for 2016 (Application Number 1609954.1) Have heard back from Patent office and no major issues highlighted. Several clauses deemed novel.
PTO application made Sept 2017. 
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
2
Read more
Hide details
Anonymous 01/02/2018 - 15:39 Sign Posted 1 comment
0
0
Votes

Innovation 'Elevator Pitch':
 
Lincus Integrate is a codevelopment collaboration between Rescon, Worcestershire Telecare, the Council and NHS that will analyse and share information from services, software and devices to improve clinical outcomes and stimulate regional growth. 
Overview of Innovation:
Lincus Integrate will create an integrated digital hub that surrounds a patient/service user and can connect with different health and social care systems, software applications and devices. It will analyse individual and grouped data providing insights through targeted visualisation to individuals, carers, health and social care professionals, managers and commissioners. Each user type will have customised access permissions and a user interface that has been co-developed with them and is appropriate for their needs.

Worcestershire Telecare (Worcstelecare) are rapidly expanding and to fulfil their ambitions to provide high value health and social care services to service users/patients they require a digital technology that will integrate with a range of  systems, digitial products and devices. Through a formal market scoping exercise they have selected Lincus, an at-market CE marked software as a platform product, to realise their goals.

Rescon’s Lincus platform has been chosen as the development platform as it has been codeveloped with end users and health and social care customers in the UK since 2011, and has numerous accreditations and awards. Rescon are working with Worcstelecare to integrate and develop the Lincus telehealth product to meet their full requirements (see attachments).

Lincus already integrates multiple digital evaluation technologies including patient self reporting, structured clinical and social care observation, and wireless devices including wearables and remote sensors. Currently there are 3600 users and 700 health and social care workers on the platform. As well as subjective and objective measurement of user health and wellbeing, it incorporates alerts for changing health and wellbeing markers, educational content, a calendar with reminders, planning, video and email/SMS communication functionality and meets high accredited information and clinical governance standards.

Lincus Integrate requires development work to further develop connections between services, other digital products and devices. It requires further refinement of user types with more discrimination between different service providers including GP, specialist, nurse, OT, physiotherapist, teleservice operator and community nurse specific interfaces.

Health Innovation funds will accelerate the development, adoption and delivery at scale of this unique integrated service proposition improving patient outcomes and generating wealth and employment for the West Midlands.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Lincus Integrate will build on previous work by Rescon and Worcstelecare that has demonstrated improved health and social care outcomes. Lincus is an NHS AHSN Atlas Product (http://atlas.ahsnnetwork.com/lincus-improving-self-care-and-wellbeing/) and has been used in assisting the delivery of health and social care services to people with Long Term Conditions, Learning Disabilities and Homelessness since 2013. For hypertension screening and support services Lincus use in partnership with a local service delivery charity produced at 3.21:1 return on investment in year for the Liverpool CCG.

Our Worcstelecare and Lincus integrated health and social care system solution is expected to save significant costs to both NHS and local government services whilst improving patient/service user outcomes. Preliminary modelling demonstrates a 10% across the board saving in social care provision through decreasing care needs. In addition, as lack of coordinated social care provision is a common cause of delayed discharge, we forecast that Lincus Integrate will decrease hospital inpatient resource load by at least 10% whilst decreasing readmission rates by 20% freeing up NHS resources to deal with those who need acute clinical care.

The Lincus Integrate system is applicable to multiple long term conditions and care needs. Using COPD as a working example Lincus Integrate is compliant with NICE Guidelines (CG101,2010) and will reduce non-elective inpatient COPD admissions (£1960/admission), or nationally >£160 million per year, (CG101, NIHR 2011 addendum).

Lincus Integrate will realise these savings through
1.) Sharing patient vital signs and other in community evaluation information across systems where
it will be used for better informed decision-making;
2.) Sharing and preemptively addressing social care issues prior to, or at the point of, potential admission;
3.) Creating a robust and continuous audit trail relating to patient data;
4.) Presenting information in a way that all the appropriate people in a patient’s care pathway (include patients and carers) can act on in a timely manner; and
5.) Integrating alerts and notifications for either routine, or rapid responsive, use.
The team is already working with the local STP and Council who are receptive and supportive of our approach including our evaluation of 10% reduction in social care needs, 10% reduction in bed days per admission, and 20% decreased readmissions whilst improving the health and wellbeing of citizens.
Initial Review Rating
4.60 (2 ratings)
Benefit to WM population:
Worcstelecare has an exemplar telecare service which has been accredited to the highest level and has been selected as a partner with the local council to integrate health and social care service delivery in Worcestershire. They currently deliver services to 17,500 service users with mixed health and social telecare needs from West Midland bases, including their head office in Kidderminster. As a result of this partnership Rescon has also created a base in Kidderminster, and a staff member in Little Malvern, to further support their West Midlands activities.

Worcstelecare’s unique partnership agreement with Worcestershire County Council, formalised in January 2018, is addressing health and social care needs across Worcestershire. A 55 person scale-up pilot is commencing in April to test the new integrated model of care which has the aim of exceeding the care, discharge and admission metrics described above. This will be expanded across the West Midlands improving individual, community and population health whilst decreasing the load on the health and social care system and creating wealth and further jobs in the region.
 
Worcstelecare and Rescon's reach extends both nationally and internationally and there is interest from both partners existing customer base to extend the model to other regions. This will result in growth of both businesses amplifying the wealth and employment benefits to the West Midlands.
For Rescon a three year forecast of the impact of the Lincus Integrate project will have on company revenues has been uploaded in the attachment section.
Current and planned activity: 
Rescon are actively engaging and working with Worcstelecare to develop and implement the long term vision of Lincus Integrate (see attachments). The partnership has been engaging with the council over the last few months which has extended to working with local clinical teams. The first clinically driven issue the combined Worcstelecare, Rescon, Council and NHS partnership is working on is that of "frequent flyer" admissions. 

Rescon and Worcstelecare are due to commence formal work in the last week of January, but have limited resources to realise the ambitions of the project over a short time frame. The attachments outline the planned work in both infographic format and as a top level project plan. The direct development cost of this activity to Rescon is £130,000. Worcstelecare have secured £55,000 to commence activities however there is a considerable shortfall which the Innovation Fund would directly address, accelerating speed to market and revenue generation.
What is the intellectual property status of your innovation?:
The combined integrated service and technology delivery model will be owned in partnership with Rescon and Worcstelecare. The working model is that the service delivery intellectual property will be retained by Worcstelecare whereas the technology intellectual property will be retained by Rescon.
Specificallty relating to intellectual property owned and being developed by Rescon all related trademarks (Lincus, Rescon, Wellbe, One Precious Life, Rescon Technologies, -tracker, IoT-Med), IPR and copyright of source code, designs and algorithms that will be utilised for Lincus Integrate are owned by Rescon.

Lincus Integrate will utilise 2 granted patents: Medical symptoms tracking apparatus methods and system (US8941659, 9754075)

It will also leverage technologies developed from the following pending UK and International patents including:
Differentially weighted modifiable prescribed history reporting apparatus, systems, and methods for
decision support and health (IT: 20160379511) and Session Limited Passcode for Re-authentication
(US62468359)
All the searches carried out for prior art have indicated that there is freedom to operate.

Strategy for knowledge protection:
Our knowledge protection strategy involves frequent IP audits with literature scanning including patents.
We make protection decisions on the basis of patentability, defensibility, costs and exploitability. The intellectual property realised by Lincus Integrate will be secured in accordance with the above strategy.

Regulatory requirements:
Lincus Integrate software will be developed out of Rescon's existing software platform technology which has multiple accreditations including being a CE marked Class 1 Medical Device, GDPR compliance and IG certifications. Our CE marked Class 2 diagnostic algorithms relating to arrythmia detection may also be utilised by the platform depending on further engagement and requirements of clinical stakeholders.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Regional Scalability:
Lincus Integrate will be rapidly scaled through the partnership with our at market partner, Worcestershire Telecare.
 
We will build on the success and scale of the Worcestershire Telecare service.  Our previous at market activities have not been with a highly ambitious partner who has a growing service.  Through the partnership we are expecting to rapidly scale both locally and then nationally and internationally with the scaling up accelerating as more features are added.
 
This at scale adoption will be only be achieved through evidence of success.  The evidence will be leveraged both locally and also used to create marketing materials to create further uptake outside the West Midlands and into the European marketplace, where we have strong contacts, especially in Spain.
Measures:
Worcstelecare were first attracted to Lincus due to its comprehensive and configurable capability in measuring outcomes of service provision.  

We intend to realise and measure the following outcomes:
  • Savings release through increasing efficiency of care delivery via new proactive preventative teleservices, and better communication systems.
    • Measurement: will compare costs post intervention with historical data and predicted spend based on profiles (regional social care data available), we will base healthcare outcomes analysis on disease specific models such as the Cardiff Diabetes Model.
  • More social inclusion and improved patient experience through wider reaching communication systems and processes. The proactive telecare model demonstrably improved health and social care outcomes including inclusivity amongst the elderly in Spain (Cabrera-Leon et al 2013).
    • We will measure both platform engagement and patient self-reported and assisted reported outcomes from baseline introduction into the programme.
  • Harm reduction through better communication and proactive care.
    • We will monitor events, interventions and incidents reported and compare to historical data.
  • Improved identification and profiling of frailty with the output of tailored personalised care plans best utilising local resources. 
    • This will be measured through cases profiled, new diagnoses and care plans.
  • Better or stabilised quality of life for service users, and carers and support staff through better systems support.
    • Measured through self and advocate-assisted report.
  • Reduced GP visits, hospital admission and delay in admission to long-term care.
    • Comparison of attendance figures for both emergency and routine admissions.
  • Increased jobs and turnover within the West Midlands.
    • Employment metrics for both Worcstelecare and Rescon.
  • Increased exports locally and internationally resulting in considerable inward investment into the West Midlands.
    • Audit of finances.
Adoption target:
Our primary adoption target is for Worcstelecare to commission Lincus Integrate for the 17,500+ users they support.  The minimum viability levels for Lincus Integrate to be sustainable is 13,700 users at £35 per annum to cover support and development costs of £40,000 per month. 
 
Read more
Hide details
Tom Dawson 21/01/2018 - 17:11 Sign Posted 1 comment
3.7
1
Votes

Innovation 'Elevator Pitch':
Airglove patient warming system heats the arm raising fragile/hidden veins providing easier/less painful access.
Overview of Innovation:
Airglove is a unique warming system was developed to enable access to the patients arm for the delivery of intravenous drugs. These patients are some of the most difficult to cannulate who have hidden or fragile veins from continual cycles of chemotherapy. Airglove gently heats up the patients arm as it forces warm air though a double walled polythene glove set at the selected thermal regulation (31.5c, 35.5c, 38.5c) in just 3 minutes. The completed service evaluation by the Maidstone & Tunbridge Wells NHS Trust showed 87.5% success in cannulation on first attempt with the most difficult to cannulate patients.  With cannulation success, the potential cost savings on consumables are up to £50k per oncology unit, plus the nursing/practitoners time. Airglove is also currently doing service evaluations in the following hospitals: Royal Stoke, Royal Marsden, UCLH, and Queen Romford.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Wealth creation / Clinical trials and evidence / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Airglove was developed initially for chemotherapy patients who have hidden or fragile veins and especially in patients who are in their 5th or 6th cycle of therapy.

The use of Airglove affords easier cannulation with fewer attempts being required (sometimes up to 6 attempts by 3 different staff can be attempted to access a difficult vein). This improved ease of access not only makes the patient’s experience far less traumatic, but ensures a better clinical outcome and saves valuable nursing/practitioner staff time and consumables.
 
Improved hygiene and reduced risk of cross infection will result from the use of Airglove vs currently used methods of locally heating the arm e.g. hot towels or buckets of warm water. Only Airglove’s single use only, double walled polythene sleeve comes into contact with the patient’s skin. Heated air is circulated between the double wall of the sleeve and is not directly blown across the skin and so the risk of cross contamination is reduced. 
 
Airglove can also be used for other interventions where venous access proves difficult due to fragile or difficult to find veins e.g. routine phlebotomy.

Maidstone and Tunbridge Wells Hospital. Evidence from trials avaliable to download 
http://www.greencrossmedico.com/wp-content/uploads/2018/01/Patient-Evalu...

"We no longer use buckets of warm water in oncology at MTW as our patients request Airglove now as they prefer it. With an 87.5% success rate in our patiemts service evaluation i can see the results which makes our life so much easier too!"
Keli Tomlin, Macmillian Lead Chemotherapy Unit Manager  – Chemotherapy Unit, The Maidstone and Tunbridge Wells NHS Hospital Trust

​"Airglove is so comfortable for our patiemts who can be difficult to cannulate with continual chemotherpy cycles. It is so efficent in just 3 minutes the patient is ready for cannulation and then theri trreatment can begin" 

Charlotte Wadey, Macmillian Lead Chemotherapy Nurse  – Chemotherapy Unit, The Maidstone and Tunbridge Wells NHS Hospital Trust

​"The warming process with Airglove is great  and very easy to use even on our patients with previous multiple cannulation and blood taking attempt.
Julia Dalstrom, Ward Sister, Teenage and Young Adult Cancer Day-care and Ambulatory Care, University College Hospital London

 
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
The West Midlands patiemts and healthcare system would equally share the benefits as described for the NHS across the UK.
Current and planned activity: 
Currently The Maistone and Tunbridge Wells NHS Trust uses Airglove in their oncology department and have just completed a Service Evaluation on Airglove. We have Airglove in the following hospitals for service evaluations: Royal Stoke, Royal Marsden, UCLH and Queens Romford. Airglove will be going into the Robert Jones and Agnes Hunt Orthopedic Hopsital and the Dudley Group of Hospitals.

NHS Health Improvement Scotland Evidence Review Commitee has advised Airglove is worthy local evaluation with the Beatson hospital, Glasgow prior to formal IMTO evidence. Airglove application has been approved to submit to NICE  for NICE Advice and NICE Guidance. Submittion has been completed MTW Service Evaluation report.

​Airglove is in process with NHS Supply Chain and NHS Scotland.
What is the intellectual property status of your innovation?:
Airglove is a registered Trademark

​Airglove is protected by international patents some of which have already been granted and others are in the application stage via our patent attorney Murgitroyd.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
We have not implemented in scale in any other region yet, as the product will not be available commercially until June 2018. From this point on it will be available to purchase across the West Midlands region directly from Green Cross Medico until available through NHS supply Chain.
Measures:
The success of the innovation will be measured by the uptake of Airglove throughout all 160+ oncology units throughout the UK. 
This will also be determined by the cost savings to the NHS, along with patient comfort and safety, which will be assessed from the success of the patient evaluation and clinical trials.
Adoption target:
If Airglove is adopted by the 13 NHS Trusts in the WM region into their respective 14 oncology units, supplying 3 Airglove units per oncology unit, this represents 42 Airglove units using 127,400 gloves per annum. 
This could generate potential savings of £369,460 per annum to the Regional NHS.
Read more
Hide details
Sheena Jack 10/01/2018 - 18:12 Sign Posted 1 comment
3.9
2
Votes

Innovation 'Elevator Pitch':
We connect people with a mental crisis to practitioners using a smartphone in an instant. Irrelevant of culture, language, or geography, instant access to counselling will be swiftly available, affordable and secure.
Overview of Innovation:
The launch of TOSPS (The One Stop Psychotherapy Shop) as an online secure platform from which therapy can be both sought & delivered lends itself to a real opportunity to revolutionise the way face-to-face crisis mental health therapy is delivered to people in need, in any location via the introduction of a crisis care platform.
It is vital that people have an opportunity to be assessed as quickly as possible before a crisis point is reached, therefore the development of a minimum interaction app to compliment the TOSPS web site is vital to ensure that people in (or approaching) a crisis are connected to a therapist quickly.
Background applications can enable complicity with NHS, Local Authority & 3rd sector mental health service provider’s requirements & interact with the digital systems records, booking systems within one application. An affordable application that is nondependent on any particular proprietary platform.
Early detection trigger guidelines allow quick diagnosis & referral to treatment for the client. Alerts to service users, carers & professionals when risks of crisis within individuals are elevated, prompting a call from a therapist or practitioner where applicable.
This app ensures that getting help & or treatment is as simple as ordering a pizza, To assist users, all of our registered therapists display our unique “on-line” light showing that they are available right now to provide instant help. The app can analyse stress triggers & alert people to potential looming issues, & seek early prevention treatment & can link to applications such as iHealth & S Health.
Payment modules can be adapted for pre-booked appointments or after event payments. Some people may wish to approach things methodically & be directed to the Mother web site, others who are in advanced crisis can be connected to immediate help via the app. The security protocols are already developed to reach current IGSoC compliance HIPAA & peer to peer security is established.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Reduce waiting time within the NHS by providing a pool of therapists across all sectors and specializations to be available at all times for emergency crisis intervention therapy and early diagnostic triggers.
Doctors and emergency services would have a central point of call with said pool of therapists who are available to provide face to face online counselling sessions in real time, day or night .
Reduction of waiting time has a positive effect on the reputation of local NHS facilities. The introductions of a central point of contact for therapy online would complement and provide the newer and more modernised NHS with a natural extension to its future modernisation programs in the deliverance of new methods for client access to crisis therapy, using the technologies the public already use on a day to day basis, phones tablets etc.  
Early intervention will reduce cost of treatment in the short and long terms. People can effectively access counselling from home thereby freeing up seats and room occupation.  Effectively the client pays for their own cyber space as opposed to the costs of the provision of therapy rooms and space.
Emergency room on call crisis mental health teams can see a relief from the growing numbers of people needing mental help assistance in the A & E. A triage type system implemented directing those in need of counselling either direct to a practitioner online or to a hospital department will streamline priorities. Cancellation time loss can be recycled. Run over time can be reduced as the client’s portal closes as soon as the session allocated time has finished. 
Safety to staff and clients is enhanced as there is no physical presence. Holiday and sickness schedules would no longer impact on the availability of counsellors, The pool of available therapists can expand and decrease to meet demand.
Geographic boundaries are removed and a greater pool of therapists are available. Therapists with free time can instantly be available to work. Language skills and multicultural issues can be less hindrance, as availability of specialized counsellors with extra skill sets can be found instantly.
Emergency triage of crisis mental health care can be portable, particularly in suicide situations. A seamless way to integrate private and NHS staff to provide counselling in times of public crisis and emergencies such as acts of terrorism or acts of God will be in place. 
Initial Review Rating
4.40 (2 ratings)
Benefit to WM population:
The West Midlands is a densely populated area; the residents are very diverse, multicultural with wide ranging needs. 
TOSPS has counsellors and therapists with a wealth and bounty of specialisms bringing with them an abundance of different language skills, English to Swahili, African, Asian, and European languages, a wide range of backgrounds, cultures, skills and knowledge would open counselling up to ethnic minorities who might shy away from help due to cultural inhibitors, fear of violence, shame or adversity.
The availability of therapists to meet their own cultural requirements without fear of prejudices is a key for some minority groups.  
The system caters for multiple needs, the 24/7 availability means that shift workers or people who experience crisis at all times of day and night will have access to someone who will help them.
Interactions with the app, intentional or unintentional, can act as a conduit to signpost people in crisis to the correct people for help. The socio-economic effect on work place downtime figures will improve as time away from work travelling to and from appointments can be removed.
Calibration with the Police and other social help associations like suicide watch will offer a portable crisis care that will assist them in their roles on the ground. The domino effect of assisting individuals take control of their mental health will filter through to the family environment.
Push notifications will remind people of follow-up appointments, and assure them that their practitioners have been notified of current or prior episodes.  
Large exhibition centres and train stations will be able to send push notification advising mentally vulnerable people registered on the system what to do in times of crisis, terrorism.  Alleviation of waiting times within NHS will promote a real improvement which will be noted by the people.  The app will empower those who often feel powerless and deliver an element of control back to those patients and can act as a buddy system bringing comfort to the mentally ill.  
A more settled and happy community who will support their NHS when they can see or hear that real progress has been made in the reduction of waiting times and costs to their NHS.  Instant access gives them control and boosts confidence. Portability of the app means counselling can be physically brought to the client any place. 
Current and planned activity: 
To grow the numbers of therapists currently registered to provide counselling online both mainstream and crisis care intervention to a start headcount of 400 therapists initially. This would provide scope to have 6 teams of 66 therapists online in 4 hour shifts across a 24 hour period. Training is already underway to ensure that each therapists IT equipment is cyber safe and certified on an  annual basis to protect data and patient confidentiality.
To develop a single point TOSPS app that can deliver all the benefits previously detailed whilst allowing the NHS to track patient costs / usage / progress automatically and work on a NHS agreed pricing and invoicing schedule for covered therapy. Additional therapy could be purchased directly by the patient or family members to supplement NHS treatment and referral fees could be offered back to the NHS to fund research into the benefits of online therapy to further promote the services and reduce overall costs of care
What is the intellectual property status of your innovation?:
TOSPS own all the rights to the name TOSPS and the delivery platform. The TOSPS app will be owned by TOSPS and their developer Proxicon who will continue to develop and maintain the app. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
The model can be classified as Simple scalability : 
Measures:
Due to the nature of the service we will be able to provide in depth reporting on the number of referrals received which have had a successful outcome in terms of delivery, we will be in a position to deep dive data which will show the number of therapeutic hours being delivered over any given time period and relate these back to specific NHS referrals.
We also believe that by engaging with NICE and IAPT and inviting them to independently monitor the quality of service and outcomes, we can confidently report on the successes and the learnings as TOSPS moves forward with the NHS.  TOSPS.com will also commit to working with other external agencies within the NHS and beyond to further understand the outcomes of its service with a view to continued development its services, feedback will be essential not only from clients but also from referring partners and charitable organisations.
 
Adoption target:
Currently the infrastructure to deliver this service is in a state of readiness; We believe that in order to launch effectively for WM NHS we will need in the region of 400 additional therapists. We will need some support from the NHS in the form of internal marketing to NHS therapists and referring agencies,
Rejection Reason:
Suitability of model to NHS
Read more
Hide details
Bernadette Bruckner 09/09/2016 - 11:20 Rejected Login or Register to post comments
2.7
1
Votes

Innovation 'Elevator Pitch':

GiveVision SightPlus is user-friendly internet connected technology that addresses wellbeing, needs and aspirations of people living with sight loss. It is a wearable vision enhancement glasses - that enable visually imapired to actually see again.
Overview of Innovation:
According to European blind Union age-related eye conditions are the most common cause of sight loss in Europe with One in three senior citizens over 65 facing sight loss. A common misconception is that blind persons cannot see anything at all. This is of course true for some but there are four times as many partially sighted, as there are completely blind. What’s worse is that existing sight aid solutions don’t give real independence to older adults living with sight loss. Industry haven’t seen any innovation in 25 years and is still limited to magnifying glasses and CCTV systems.

SightPlus, enables partially sighted people to see again by combining real time video augmentation with heads-up display technology to leverage their remaining sight. The tool empowers partially sighted people to be able to see faces of their loved ones, read printed and digital text, recognise signs and objects at a distance, watch TV and stay connected over the web.

SightPlus is built on existing hardware platform (i.e. Android smartphone and VR headset) resulting in a scalable and much more affordable product compared to existing tools. It can also communicate with a wide range of other smart devices as it has embedded connectivity. For purposes of immediate assistance and tech support - all of our devices come  with a 4G SIM card to ensure that our customer stay connected even when there is no WiFi network available.

Our technology is designed to offer new ways for visually impaired people to interact and experience the world around them, unlock their independence and mobility, and significantly increase their quality of life by empowering them to continue to lead independent lives and play an active role in society, whether that be at home, work, education, or in their community.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Reduced numbers of admissions and reduced care costs.
Online Discussion Rating
5.00 (1 ratings)
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
Obvious benefits for people living with Sight Loss and their families. Users are more independent and mobile, reduced care costs, reduce risk of depression and other mental health problems
Current and planned activity: 

We estimate that at the current rate of beta-testing we will have reached our tester sample goal by early next year, raised new round of funding in spring 2017 and the product on the market by next summer. However, winning the prize would allow us to speed our development up significantly and get SightPlus on the market (including other European Countries) as early as February 2017!
What is the intellectual property status of your innovation?:
Patent drafting
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
Please describe how the innovation could be scaled across the WM region. Have you implemented at scale in any other regions?
Measures:
What outcomes are you hoping to achieve and what are the measures that you will use to gauge the success of the innovation and how will these assessments be made? Please ensure that you have quality, safety, cost and people measures.
Adoption target:
What are the targets for adoption across the WM and what are the minimum viability levels?
Read more
Hide details
Stan 30/08/2016 - 14:26 Approved Login or Register to post comments
4.7
1
Votes

Innovation 'Elevator Pitch':
Life Echo is a therapeutic personal phonic map of patients positive memories to reconfirm and generate memory management and interaction and how they can approach death.
 
Overview of Innovation:
Wiggan has discovered the possibilities that phonic recordings offer social care and Life Echo could offer alternatives within therapy and the skills of hearing that can address deep emotional and mental struggles.
 
Life Echo will address some of the issues relating to dementia and bereavement. (Primarily in first stages, then into other areas) and that Life Echo will explore the impact of sound on mental and emotional wellbeing. 

Previous activity has been building the project on the notion that hearing is one of the last senses to leave when a patient is terminally ill, this could possibly change how people interact with their own memories and how they can approach death.
 
This first stage of the project had shown it has great potential to become part of the service provision in end of life care and could be rolled out beyond the local area to become citywide and possible a regional or national project.
 
Positive memory trigger points with individuals receiving end of life and palliative care at the John Taylor Hospice in Birmingham and early sufferers of dementia to create ‘Life Echoes’ or personal phonic maps create this work.
 
The process encourages patients to reconfirm or establish memory routes, generating deeper, more intensive memory emersion through sound recall.
 
Life Echo is the sound of patients positive memories, as they consider an age or time period that has a positive significance for them, for each person this will be different and unique.
 
The Life Echo is an experience, alone or with family/ carer/staff. It is not a sound track of sound effects, but an abstract, therapeutic sound narrative based on the data shared by the patient.
 
 
This programme impacts upon end of life care and enhances the possibilities of ‘dying well’, it leaves a tool for the participant, a legacy for the family and potentially offers a process to delay the early on set of dementia.
 
Life Echo has the potential to become part of the service provision in end of life and dementia care. 

Life Echo is at inception/ R&D phase, so measurement guidelines are not yet fully formed. Anecdotal evidence, through film recordings and written documentation suggests that participants are extremely positive towards their experience however, this positivity needs to be formalised in order to establish clear frameworks for assessing success. 

The next step is to evaluate the impact of Life Echo on user, carer and family and develop a digital self perscription version
 
 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
 Our proof of concepts studies plus the 18 months of ongoing implementation of Life-Echo in the setting of our base West Midlands hospice have given us very considerable confidence to describe the followings features among those patients in whom increasing memory deficit is an pressing and relentlessly increasing daily problem.
  1. Promotes welfare benefit
[Increased and noted positive mood up-lift for the patient and more general care & welfare benefits]
 
  • For the patient : elevation of affect, pleasure and increased tranquility
 
  • For the carers : additional benefit and assistance to those directly managing their daily care, and more generally in improved mental accessibility of the patient towards close relatives and carers sharing their daily life
 
  1. Delivers financial benefit
  • Essentially in terms of increased quality time salvaged (due to the patient’s lighter affect and increased communicability) 
  • Reduced difficult times of wearisome management  (due to mental inaccessibility of the patient)
 
  1. Motivates the seeking out of further application areas and business
  • The Life-Echo business, small as it is, has over the last four years been approached by some twenty different potential users of the equipment and ideas in a truly impressive range of situations – schools, adult education, mental health therapy, relaxation for stressed children and adults in hospitals, prisons, detention centers as well as for well and healthy individuals in challenging and extreme circumstances.
 
For one reason of another [possibly because the technology is eminently affordable and flexible in design and because the fundamental idea of access to personal memory and imagination is so alluring] Life-Echo is overflowing this development possibilities. For those purchasing Life-Echo it is so easy to use in opening up new application areas. Indeed in situations like hospices and hospitals for these possible developments can readily be viewed as revenue generating.
Online Discussion Rating
5.00 (1 ratings)
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Presently our experience is in the palliative day-care setting, where even if this were to be the only application are, we would base the computation on exactly the three areas shown in detail above; and moreover these would need to be delivered by a system which costs in a Life-Echoist  at each of the three stages – mapping, creation, reproduction.
 
[Nevertheless, our present direction of technical development is for Life-Echo to be both self-derived and self-administered – which opens up the option for creation to be Life-Echoist –supported or even self-created.]
 
Simply applying to Life-Echo the epidemiology of dementia in the over 60’s population of West Midlands 
http://www.alzheimersresearchuk.org/about-dementia/facts-stats/10-things-you-need-to-know-about-prevalence/

and on the basis of the benefits described at A, above:
 
            Promotes welfare benefit :
  • Over 1.5 million people in the UK (West Midlands at 8.85% = 130,000) therefore, including both people with dementia and their carers, would potentially benefit from dementia treatments today.
 
Delivers financial benefit :
 
  • Per patient day using Life-Echo we estimate a conservative net financial benefit of £10.
 
Motivates the seeking out of further application areas and business: 
 
  • Per institution adopting Life-Echo per year we estimate a conservative ‘novel usage’ return to them of between  £2k and 20k per year.
 
If Life-Echo looked to monetarizing for its own return just 15% of this potential customer gain then for every 80-users that would be 15% of £((80*365*10) + (3*5,000)) = £46,000
[based on present situation of 80 users in 3 centres for a single year.]
 
This is the present base level (£46k p.a. 2016) – and we expect to increase this 10 fold in 1 year (£460k p.a. 2017) and 100 fold in the following 4 years (£4.6m p.a. 2021)
Current and planned activity: 
Life Echo is  being considered with the Q.E wellbeing team for the YPU Cancer Ward and Dementia Ward , who have seen the postive impact and change it can bring to patient and carer / staff prioritsed costings have limited thier engagment at this point . Anthony Cobley was championing the project to be at the Q.E. John Taylor hospice are a keen stakeholder as the porject started there and they are eager to see it develop. There are also other organisations waitng to run in part ir full programme . These are St.Andrew's Forensic , T.E.A Project in Sri Lanka , Cotteridge School, Newton Dee in Scotland ,SIFA, Ty Hafan ,CRISIS Birmigham and HMP Brimingham. (see supporting document for more details ). In terms of development support there is interest in its software translation potential from Microsoft and EnablediD. If successfull with this funding to develop a digital memory atlas and / or evaluation on patient / carer diginty , then these partners will be secured for next phase. 
 
What is the intellectual property status of your innovation?:
Life Echo as a name and logo is trademarked , however the copyright and patenting of IP , process etc are not yet completed but in progress right now. ( This is where guidance and support is requred .) I realise the extreme importance of this and do need to get that done , however this needs a £3000.00 injection now to get this status complete.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Regional Scalability:
West Midlands Region

1. Via our four Life-Echoist Training Courses planned for 2018 at three different palliative care locations and University Venue: 
  • John Taylor Hospice
  • Myton Hospice, Leamington Spa
  • Compton Hospice, Wolverhampton
  • BCU, Well Being and Digital Health
Each will train eight Life-Echoists:

2.  Via the 2018 Life Echo Conference – December, 2018
 
3.  Via the excellent offices of WMAHSN
 
Other Parts of the UK

We are currently working in Wales with both Children’s Hospices:

Tŷ Gobaith, Conwy
Tŷ Hafan, Cardiff

With further discussion:

HMP BIRMNGHAM
CRISIS
SIFA FIRE SIDE 
Measures:
2 known areas of personal impact (preliminary medical & social history/psychological/physiological)
 
1. Patient’s short & long form: Enhancing function, promoting relationships & social participation & finding ways for those with dementia to enjoy life are the keys to successful occupational therapy intervention. Providing education for family, care providers & clients (as they are able to understand) & promoting the persons strengths will ensure that those with dementia & their care providers have the support needed to live life to its fullest

2. Carers/Staff: The medical & clinical background to these choices is explained more fully in our Measurement Notes for the LE-Corpus
 
This application is about Life-Echo as a health care intervention, particularly the patient with early dementia symptoms at home or in a residential/palliative care environment, along with carer(s) & medical professionals. Everything that follows here will therefore be directed to the needs & benefits of those 3 groups. However it is important to have in mind that Life-Echo already has authentication in its use from a range of other fields where its users & critics have made us aware of the depth of its effects & the impact it has had on them
 
Life-Echo moves the individual & motivates their behaviour & that is the common denominator of all that we have in growing corpus of our evidence. That corpus is held in a customised SQL database designed for linguistic analysis to extract sentiments & feelings across a psychological & physiological theoretical domain. Data is very carefully & painstakingly collected according to the framework (outlined in attached ‘Measures’ document). Moreover this is done in a way that as far as possible means that no recorded encounter with Life-Echo goes untapped for new or confirmatory insights into its workings
 
Full information on the measures to be used to gauge the success of Life Echo & how these assessments will be made are in the attached ‘Measures’ document
Adoption target:
Rejection Reason:
Needed to focus on one application.
Read more
Hide details
Justin Wiggan 21/06/2016 - 06:37 Rejected Login or Register to post comments
2.9
1
Votes

Innovation 'Elevator Pitch':
OrthOracleTM – Multidisciplinary on-line orthopaedic educational resource for clinicians, industry, academia and patients
Overview of Innovation:
The training of surgical specialities in the UK has both shortened and is less intense due to the combined effects of a restructured medical training and the European working time directive.
As these influences have been felt over the last decade the resources available to educate both surgeons and the medical workforce have not evolved to account for them. There is far greater requirement to demonstrate continuing education.
 
Allied with this are increased expectations from patients both in terms of their outcomes and level of information available to them to assist in making more informed choices about their healthcare. Increased professional regulation and a requirement to annually demonstrate appropriate levels of professional supporting activities are also areas where a high quality resource delivering validated CPD outcomes has huge potential.
 
Surgery is an inherently visual discipline and the optimal demonstration of its techniques requires the clear illustration of human anatomy as well as it’s adjustment. Existing educational resources do not reflect the interdisciplinary nature of orthopaedic practice nor provide the range or quality of material that is required today.
 
Each Atlas will document the management of a patient from initial assessment through to surgery and then to rehabilitation. Surgical procedures are detailed with high definition images and commentary provided by a Board of senior Consultant Surgeons. Implant technologies for each procedure link directly to industry information.
 
Data is managed to allow different website front ends to be displayed for differing  members of the wider healthcare team and patients. The rich data will support the future development of simulation tools.
 
Boards meet regularly to review new procedures, best practice, patient safety and guidance, medical technologies and research.
 
OrthOracle is not just a digitised text book; it is an interactive web based resource, written by practicing clinicians bringing together the best in clinical practice and orthopaedic technologies covering the entire treatment pathway and facilitates collaboration between clinical, academic and industry sectors leading to improved patient outcomes.

www.footsurgeryatlas.com

The OrthOracle concept has been tested via an early version of The Foot Surgery Atlas, launched in 2007 which, despite no advertising, regularly received over 55,000 hits per month 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
OrthOracle directly support NHS workforce development .
 
The content of OrthOracle is produced by a Board senior practicing surgeons and healthcare professionals working within the NHS and private sector, helping to promote and disseminate best practice in all aspects of the healthcare journey.
 
The management of workforce issues such as CPD and revalidation are assisted by the provision of approved and certified educational materials ((ongoing discussions with Royal College of Surgeons (Edinburgh) in partnership with Birmingham office and other Healthcare , Allied Healthcare regulators and bodies)).
 
A planned secure clinician and patient specific interface for real-time outcome monitoring will assist with safe and optimal patient management.
 
Patient focussed information on their operation, rehabilitation and consent will enable patients to be better informed and prepared for their treatment. This will involve the patient more actively in the process leading to more efficient use of resources and with the aim of improved outcomes.
 
The availability of such a dynamic educational resource 24/7 facilitates training provision, is cost effective and ensures knowledge of procedures is up to date thus ensuring a better informed workforce with improved patient outcomes at all levels of professional practice.
 
Collaboration with QEH Clinical Photography department in developing advanced image capture technologies and protocols.
 
Board meetings regularly bring together NHS clinical consultant with industry to facilitate dialogue on implant development with potential commercial and research spin off benefits for the NHS.
Online Discussion Rating
5.50 (2 ratings)
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
OrthOracle has a global reach. Based in Birmingham with planned events within the Region, supports the Region’s international profile providing a showcase for academic, clinical and industrial skills creating opportunities for the development of new clinical skills, training and product development.
 
It is envisaged that the editors in chief of the 5 additional Surgical Atlas’ (hip, knee, shoulder, spine, hand & wrist) will be recruited from West Midlands Trusts. A number of the additional 25 contributing editors will also be from West Midlands Trusts.

In addition, project support and administrative staff will be sourced locally from within the region.
  • 6 speciality Boards meeting 3 times per year to be held regularly in West Midlands
  • Unique opportunity for industry to gain regular feedback from Consultant Surgeons
  • Potential for creating global opportunities for West Midlands organisations in new product development, research and training.
  • The multidisciplinary scope of OrthOracle and its high profile internationally active Editorial Boards support the hosting of an annual Digital Orthopaedics Conference which we hope will be based here in the region.
  • In consultation to directly support the proposed Medical Technologies assessment hub
  • OrthOracle creates a global clinical research nexus and hosting opportunity for surgical training, virtual and augmented reality training products and facilities
  • It will also provide Human Factors, User Experience design and multidisciplinary healthcare integration building upon existing world class regional strengths
  • Opportunities for the development and delivery of medical related educational programmes and CPD modules via regional organisations, in association with professional bodies, Royal Colleges and regulating authorities.
  • OrthOracle will immediately create new jobs and support existing employment locally; growing rapidly as additional Surgical Atlas’ and content develops.
  • Look to Developing a global training focus on Orthopaedics here in the West Midlands, building from the position the region has held for many decades in orthopaedics expertise.
 
NOTE: This training platform has the ability to cover a wide range of surgical fields – following the success of Foot & Ankle we will be developing other orthopaedic areas as well as inviting other renowned surgeons to develop their own speciality areas from this foundation.
Current and planned activity: 
Editorial teams members provide Consultant medical services directly and indirectly to the NHS across numerous regions.
 
Clinical photography services of QEH will provide all OrthOracle photography services and project represents a FTE dedicated post. These services are currently being used for the Foot Surgery Atlas.

Planned activities
  • Engage with Health Education England re: workforce development.
  • Seek  Regional surgeons to join Editorial Boards
  • Continue discussions with RCS (Ed) & other AHP bodies, specialist groups and regulating authorities re: partnership, accreditation and CPD
  • Establish a project office
  • Develop a robust marketing strategy/plan
  • Develop sustainable business development strategy/plan
  • Seek Regional participants to assist in evaluating and developing the training delivery process
  • Undertake scoping study re: surgical simulation and augmented realitywith University of Birmingham Prof. Alan Wing & Prof Bob Stone 
What is the intellectual property status of your innovation?:
OrthOracleTM is a registered Trademark
 
All images in each Surgical Atlas are digitally watermarked and site content monitored to protect from unlicensed data stripping.
 
A policy relating to patient photographs and IP issues applying to all Editorial Board members’ organisations is currently being finalised.
 
A specialist IP legal advisor is retained by Surgical Armoury Ltd to manage should an IP issues arise from the OrthOracleTM project.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Regional Scalability:
The individual Atlas’ within the OrthOracle and supporting information/services are delivered on-line and so availability is worldwide and at scale.

Additional Orthopaedic surgical specialities will be rolled out as soon as editorial boards are in place using the same procedure capture format. Current plans are for Hip, Knee and Shoulder sections to be undertaken this year as Editors in Chiefs have been identified and are all prominent West Midlands Orthopaedic Surgeons.

Where possible all contributors and service providers will be sourced from within the West Midlands and the project administration centre will be based in Birmingham. There is a pressing need for a Chinese language version and discussions have been held with the head of the West Midlands Chinese business community who is very keen to support the project and a regionally based specialist medical translation service has been identified.
Measures:
Detailed tracking of website visit statistics will be undertaken and the number and nature of individual visits will be captured and reviewed. Page specific statistics will be interrogated to establish where the page/site design can be refined. Log in data will be collected and generates geographic, organisational, professional and demographic data of the user population. Additional information will be directed to specific groups as appropriate.

Several areas of the site, such as general surgical images and data will be available as a Freemium service, however a stratified subscription model is currently being developed for individual and organisational users who wish to access the wealth of supporting information and services such as the ability to create individual and annotated versions of specific procedures, clinical administration documentation such as patient consent forms, patient guides, access to  research/evidence database, CPD content.

The provision of quality accredited CPD material is a core deliverable of OrthOracle and advanced discussions with The Royal College of Surgeons (Edinburgh) are ongoing with their President, CEO and Head of Education. The College is keen to support this project from their Birmingham offices. Other accreditation and provider bodies have been identified and approached.

A user friendly CPD portal will be created to record individual user CPD in accordance with Professional/regulatory body requirements for audit and revalidation. Each surgical procedure includes specific CPD modules set by the procedure’s submitting surgeon. Individual user access times and interactions can be recorded to facilitate site usage and page viewing metrics.

This education and training platform will be further developed through the development of associated virtual and augmented reality simulators linked to OrthOracle content (Regional partners for the development of these have been identified e.g. Profs Bob Stone and Alan Wing – Bham. Uni)
Adoption target:
Conservative business model assumes global (not WM) registered members numbering 10,000 year 1, 50,000 year 2 & 100-200,000 year 3 (Orig. Atlas had 50,000 users/mth by 2015 without promotion)

Assuming 20% take up by registered users of one or more of the pay-for services Atlas will be viable midpoint year 2

RCS(Ed) promotion to members not inc
Read more
Hide details
Mark Herron 12/06/2016 - 10:24 Approved Login or Register to post comments
3.8
4
Votes

Innovation 'Elevator Pitch':
Intensive home self-treatment of  chronic conditions  with a safe, clinically proven therapy advised    by HCPs acting remotely within a web based  “Virtual  Clinic" brings  treatment cost reduction and improves HRQoL. 
 
Overview of Innovation:
The proposed innovation establishes a partnership between the local clinicians, individual patients, Neurocare™ Europe who supply the Electrotherapy Device and Neurocare's™ partner Idieikon who have developed the web based Health and Social care management system.

There are three dimensions to the Innovation proposed.  Firstly the "Virtual Clinic" requires the specification of an appropriate mix of medical skills to man the clinic according to the condition(s) intended to be treated.

Secondly the principal therapy chosen must be safe, comfortable, suitable for home self treatment and clinically proven in the applications proposed .
 
Thirdly the patient cohort must be motivated and sufficiently computer literate to make appropriate use of the "Virtual Clinic" and to follow treatment protocols for the Therapy Device.

The Patient will also self monitor progress (in the example of treating leg ulcers) by such means as taking and uploading photographs of wound size reduction, completing  self reporting inventories for example of pain increase or decrease and undertaking any further monitoring  as required by clinicians.

Whilst any form of therapy could potentially be used within the "Virtual Clinic" concept providing it met the essential  safety and efficacy criteria. Electrotherapy, particularly Neuromuscular Electronic Stimulation has been chosen to illustrate the operation of the concept since it has a broad range of clinical evidence supporting its use in  treating many conditions where improving blood circulation,  increasing joint range of motion, improving muscle bulk and strength, resolving muscle spasms and avoiding atrophy are key to a successful outcome for the patient.

Circulatory and musculoskeletal conditions are frequently part of the aetiology of those affecting mobility and self sufficiency in later life, treatment of which in a clinical setting can be labour intensive and involve much inconvenient travel for the Patient. In addition to dermal wound healing we would expect that the concept could readily be used in  rehabilitation post stroke and post major orthopaedic surgery e.g. TKA and post bone fracture where early and intensive treatment is essential  for pre-disablement strength and mobility to be restored.

Recent clinical studies have also shown that NMES therapy can counter Sarcopenia and restore muscle mass and strength and improve balance thus enabling the elderly to remain self-sufficient in their own homes for longer.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
The three distinct aspects of the innovation proposed, Electrotherapy, Home self-treatment and the use of a “Virtual Clinic” if  adopted separately will each  improve patient outcomes, produce efficiency improvements and  be cost effective. When deployed together following patient involvement and consultation designed to improve patient activation and  reinforced by the use of patient reported outcome measures (PREMS)  further synergistic gains are anticipated.

NMES is used to treat many chronic conditions. Clinical evidence is strong in dermal wound healing (paper attached) in rehabilitation post major orthopaedic surgery e.g. TKA, ligament reconstruction etc., (paper attached). In other applications such as Arthritis, COPD, Neuropathy, and Sarcopenia   evidence  is positive but not yet conclusive.

In wound healing and rehabilitation NMES has been shown to accelerate healing timescales when used as an  adjunct to standard treatment pathways where timescales are long, labour intensive and incur high consumable costs.  Faster healing brings lower costs and in situations where the wound condition may have worsened (e.g. diabetic ulcers which can escalate into amputation) additional costs can be avoided and  the patient experience radically improved.

The use of Neurocare™ NMES therapy is safe and comfortable. The device proposed for this innovation is of unique electronic design in that it produces an AC signal of up to 400 volts at less than 10 milliamps. This allows full recruitment of local musculature for effective therapy. Inherent ease of application makes the therapy very suitable for home self-treatment which can be delivered intensively.

The use of the “Virtual Clinic” means that home self-treatment can be closely monitored by HCPs who are able to interact as necessary throughout the course of therapy. Self-measurement and regular dialogue should reduce the need for, and inconvenience of clinic attendance and save cost.

The “Virtual Clinic” is an additional feature of the Adsum+ Health and Social Care Management System which is a comprehensive platform designed to facilitate proactive and integrated care and  enhance efficiency. Amongst a full range of advanced features Adsum+ software identifies, co-ordinates and manages the activities of each person/organisation involved in the care plan, tracks activity and flags up missed or incomplete events so that remedial action can be taken.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The wealth of any nation and the health of  its population  are inter-related in complex  ways. Increases in wealth and improvements in health require  continuously rising unit productivity which in turn requires  continuous  innovation.

In the NHS , against a  backcloth of rising unit costs and  rising demand for services across the entire   healthcare spectrum, the consensus on  necessary change highlights a required new emphasis on proactive care and prevention, patient centredness, more effective integration and coordination within and between HCPs and Healthcare Organisations  and a radical reorganisation of the healthcare/social care interface together with an emphasis on chronic conditions and enabling elderly people to live independently.

We believe that the proposal contained in this paper can contribute in the following ways:
The use of electrotherapy in one of the proposed applications suggested  will demonstrate that this form of treatment on an intensive basis in a surgery, clinic or the home can significantly reduce healing timescales and costs and in many cases can be used as a preventive treatment.  It will also show that guided self-treatment is viable in many situations, particularly in treating certain chronic conditions.

Major new system implementations such as Adsum+ are often used  as a vehicle for facilitating and driving far wider ranging change in management processes and organisational culture. Implementation of this proposal contains the tools and the potential to facilitate the far deeper and broader changes required.

Technology enabled care usually defined as telehealth and telecare can play a valuable role in this transformation but the real value added gains may lie in the widespread take-up of “Virtual Clinics” and similar concepts  which put the patient at the centre of  the treatment plan.

Raising the level of  knowledge and engagement amongst the  patient population together with developing a capability to take more responsibility for their own health is crucial. The key is to convert passive recipients of reactive care into active knowledgeable participants in the management of their own general treatment when necessary.

The deployment of innovative, proven therapies locally or in the home, enabled and jointly managed by providers and recipients in the form of a “Virtual Clinic” will prove a powerful contributor to  improving health states and thereby create increasing wealth.
Current and planned activity: 
We are involved with The NHS within the Vanguard Initiative. This is at a very preliminary stage and we would welcome any assistance to accelerate this work.

We are collaborating with three Clinicians (Prof Mike Edmonds at Kings College Hospital is PI) in preparing an application to the NIHR Research for Patient Benefit funding stream. As presently constituted this will be a three centre clinical trial of web enabled home self treatment of recalcitrant diabetic foot ulcers.

In the EU we are in the process of appointing Distributors in several countries and are also involved in the HAPPI project
In the  Middle East  we are working in Iraq and Iran with new Distributors.

On a general basis we would like to hear from Clinicians/CCGs interested in any application of NMES with a view to organising adoption pilots. This could be stand alone or in conjunction with the “Virtual Clinic” concept with treatment given either in clinic, in the home, or in the Nursing Home.
What is the intellectual property status of your innovation?:
The IP in the Neurocare™ NC2000 device is owned by Neurocare™ Inc. of Salem Oregon and licenced exclusively to Neurocare™ Europe Limited. All treatment protocols are copyright.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Regional Scalability:
This will depend upon the healthcare priorities identified within the West Midlands region, since the therapy as noted in the original document has several clinically  proven applications particularly in relation to chronic conditions.
 
Two of the West Midlands priorities are the Treatment of Long Term Conditions and the Promotion of Wellness and Prevention of illness.  These two areas bearing in mind the associated enabling themes, particularly innovation and adoption, digital health, person centre care, clinical trials and evaluation and education skills, suggest that any one of several chronic conditions could be treated.  These would include, long term ulceration, muscle rehabilitation post operation and muscle rehabilitation in long term atrophy and COP for example
 
Prioritising depends on knowledge of clinicians who are interested in pilot application work of the therapy in their particular area of specialism.
Measures:
Depending on the application chosen we would expect to be able to show that through the application of NMES technology, faster healing or rehabilitation will take place.  This of itself will produce significant treatment cost reduction and in many cases will prevent escalation of the condition into subsequent stages which themselves require more intensive and expensive treatment.
 
In clinical trials generally of NMES devices in many applications over the last 20 years, there have been few if any safety issues arise or any adverse incidence reported so it can be confidently stated that the therapy is inherently safe. If the decision is use to apply the therapy in conjunction with the web-enabled “Virtual Clinic” proposed in the original paper, we are then able to implement an appropriate selection of Patient Reported Outcome measures, which allow us to track the patients experience with the therapy and record the results on whatever parameters clinicians have chosen. 
Adoption target:
It would be valuable to establish one adoption pilot in one of the applications where there is strong evidence of efficacy and to do this requires introductions to medical staff with the  appropriate level of interest and authority. Experience of  a first pilot would suggest adoption targets going forward. Minimum viability would be one unit.
Rejection Reason:
The investment committee decided not to invest.
Read more
Hide details
Patricia Forrester 10/05/2016 - 18:30 Rejected Login or Register to post comments
2.7
4
Votes

Recent Activities

Hospify has been moved from Detailed Submission to Screening 1 month 5 days ago
Hospify has been moved from Initial Submission to Publish 1 month 1 week ago
VIATEM; has been moved from Board Decision to Approved 1 year 6 months ago
VIATEM; has been moved from Detailed Submission to Screening 1 year 6 months ago
Taking preventative health care back to grass roots - community and workplace iterventions. has been moved from Detailed Submission to Screening 1 year 6 months ago

Active Campaigns